--- title: "TransThera Showcases Tinengotinib Data on Endocrine Resistance in HR+ Breast Cancer at AACR 2026" type: "News" locale: "en" url: "https://longbridge.com/en/news/283415898.md" description: "TransThera Sciences (Nanjing), Inc. presented new research at the 2026 AACR Annual Meeting, revealing that lineage plasticity from FGFR-JAK signaling contributes to endocrine therapy resistance in HR-positive breast cancer. Their study indicates that tinengotinib (TT-00420), a dual FGFR-JAK inhibitor, can restore luminal identity and resensitize resistant cancer models to endocrine therapy. This supports ongoing phase II trials of tinengotinib combined with endocrine therapy in advanced HR-positive breast cancer, highlighting its potential across various solid tumors and enhancing TransThera's position in the oncology market." datetime: "2026-04-21T00:12:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283415898.md) - [en](https://longbridge.com/en/news/283415898.md) - [zh-HK](https://longbridge.com/zh-HK/news/283415898.md) --- # TransThera Showcases Tinengotinib Data on Endocrine Resistance in HR+ Breast Cancer at AACR 2026 ### Claim 30% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) has provided an update. TransThera Sciences (Nanjing), Inc. has highlighted new research at the 2026 American Association for Cancer Research Annual Meeting showing that lineage plasticity, driven by convergent FGFR-JAK signaling, is a key mechanism of resistance to endocrine therapy in HR-positive breast cancer. Using single-cell transcriptomics and resistant tumor models, the company’s team identified a luminal-to-basal transition with ER and PR downregulation that arises in primary tumors and intensifies in metastases, particularly malignant pleural effusions. The preclinical data indicate that tinengotinib (TT-00420), a dual FGFR-JAK inhibitor, can restore luminal identity and resensitize resistant HR-positive breast cancer models to endocrine therapy in vitro and in vivo, supporting dual FGFR-JAK blockade as a strategy to overcome lineage plasticity-driven resistance. This work underpins an ongoing phase II clinical trial of tinengotinib combined with endocrine therapy in advanced HR-positive breast cancer and reinforces the drug’s broader potential across solid tumors where it already holds multiple regulatory designations, bolstering TransThera’s positioning in the competitive oncology therapeutics market. **More about TransThera Sciences (Nanjing). Inc.** TransThera Sciences (Nanjing), Inc. is a China-based biopharmaceutical company focused on discovering and developing targeted oncology therapies, particularly multi-kinase inhibitors for solid tumors. Its lead asset tinengotinib, an NDA-stage, multi-kinase inhibitor targeting FGFRs, VEGFRs, Aurora A/B and JAK, is being evaluated globally in multiple cancer indications and holds orphan drug and fast-track designations in major markets. **Average Trading Volume:** 2,482,081 **Technical Sentiment Signal:** Strong Sell **Current Market Cap:** HK$21.35B ### Related Stocks - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [159748.CN](https://longbridge.com/en/quote/159748.CN.md) - [520500.CN](https://longbridge.com/en/quote/520500.CN.md) - [562050.CN](https://longbridge.com/en/quote/562050.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159570.CN](https://longbridge.com/en/quote/159570.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [510660.CN](https://longbridge.com/en/quote/510660.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [02617.HK](https://longbridge.com/en/quote/02617.HK.md) ## Related News & Research - [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md) - [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md) - [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md) - [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md) - [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)